Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Exclusion Criteria

• •1. Acute promyelocytic leukemia (AML subtype M3)
• •2. Previous exposure to the treatment of VEN-based regimen
• •3. Cardiac dysfunction (particularly congestive heart failure, unstable coronary artery disease and serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy)
• •4. Respiratory failure (PaO2 ≤60mmHg)
• •5. Hepatic abnormalities (total bilirubin ≥2 times the upper limit of normal \[ULN\], alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 times the ULN)
• •6. Renal dysfunction (creatinine ≥2 times the ULN or creatinine clearance rate \< 30 mL/min)
• •7. ECOG performance status 3, 4 or 5
• •8. Substantial history of neurological, psychiatric, endocrine, metabolic, immunological, or any other medical condition not suitable for the trial (investigators' decision)
• •9. Active acute or chronic graft-versus-host disease (GVHD). Active acute GVHD or chronic GVHD is defined as GVHD requiring either at least 1 mg/kg per day of prednisone (or equivalent) or treatment beyond systemic corticosteroids.
• •10. Patients with pregnancy
• •11. Uncontrolled active infection
• •12. Clinically significant coagulation abnormalities